Nevro Corp

Are IPOs worth the gamble? This investment panel’s answers may surprise you

Considering an IPO? A MedCity INVEST panel of investors and entrepreneurs shared some sobering insights from their experience.

By Nicole Oran

Artificial Intelligence

Why Your Patients Are Leaving and How to Stop It

Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.

By Bryan Sequeira, Director, Product Management Greenway Health

Changes in Nurse Staffing Answer Clinician Demands

The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.

By Tomasz Rezik

Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options

FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.

By FASENRA, Sponsored Content